Tripelennamine
Pbz, Pbz-sr (tripelennamine) is a small molecule pharmaceutical. Tripelennamine was first approved as Pbz on 1982-01-01. It is used to treat allergic rhinitis perennial, asthma, and urticaria in the USA. The pharmaceutical is active against histamine H1 receptor.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| allergic rhinitis perennial | EFO_1001417 | D012221 | J30.89 |
| asthma | EFO_0000270 | D001249 | J45 |
| urticaria | EFO_0005531 | D014581 | L50 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
D: Dermatologicals
— D04: Antipruritics, incl. antihistamines, anesthetics, etc.
— D04A: Antipruritics, incl. antihistamines, anesthetics, etc.
— D04AA: Antihistamines for topical use
— D04AA04: Tripelennamine
R: Respiratory system drugs
— R06: Antihistamines for systemic use
— R06A: Antihistamines for systemic use
— R06AC: Substituted ethylene diamines, systemic antihistamines
— R06AC04: Tripelennamine
HCPCS
No data
Clinical
Clinical Trials
29 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Gallbladder neoplasms | D005706 | EFO_0004606 | C23 | — | 1 | 2 | — | — | 3 |
| Central nervous system neoplasms | D016543 | — | — | 2 | — | — | 2 | ||
| Klatskin tumor | D018285 | EFO_1001005 | — | — | 1 | — | — | 1 | |
| Esophageal squamous cell carcinoma | D000077277 | — | — | 1 | — | — | 1 | ||
| Cholangiocarcinoma | D018281 | C22.1 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | 5 | 1 | — | — | 1 | 6 | ||
| Head and neck neoplasms | D006258 | — | 3 | — | — | 1 | 4 | ||
| Lung neoplasms | D008175 | C34.90 | 2 | 2 | — | — | 1 | 4 | |
| Malignant mesothelioma | D000086002 | 1 | 1 | — | — | 1 | 3 | ||
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 1 | 1 | — | — | — | 2 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | 1 | — | — | — | 2 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | — | 1 | — | — | 1 | 2 |
| Small cell lung carcinoma | D055752 | 1 | 1 | — | — | — | 1 | ||
| Squamous cell carcinoma of head and neck | D000077195 | — | 1 | — | — | — | 1 | ||
| Squamous cell carcinoma | D002294 | — | 1 | — | — | — | 1 |
Show 4 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obstructive jaundice | D041781 | EFO_1001068 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | TRIPELENNAMINE |
| INN | tripelennamine |
| Description | Tripelennamine, sold under the brand name Pyribenzamine by Novartis, is a drug that is used as an antipruritic and first-generation antihistamine. It can be used in the treatment of asthma, hay fever, rhinitis, and urticaria, but is now less common as it has been replaced by newer antihistamines. The drug was patented at CIBA, which merged with Geigy into Ciba-Geigy, and eventually becoming Novartis.
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CN(C)CCN(Cc1ccccc1)c1ccccn1 |
Identifiers
| PDB | — |
| CAS-ID | 91-81-6 |
| RxCUI | 10847 |
| ChEMBL ID | CHEMBL1241 |
| ChEBI ID | 9741 |
| PubChem CID | 5587 |
| DrugBank | DB00792 |
| UNII ID | 3C5ORO99TY (ChemIDplus, GSRS) |
Target
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 321 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more